High-Dose Yttrium-90 Resin Microspheres Improve Hepatocellular Carcinoma Response

Hepatocellular carcinoma remains a leading cause of cancer-related mortality worldwide, frequently presenting at stages where curative resection or transplantation is no longer feasible [1, 2]. For these patients, transarterial radioembolization using Yttrium-90 microspheres serves as a critical locoregional intervention, often providing superior time-to-progression compared to conventional chemoembolization [3, 4]. While the safety profile of radioembolization is well-established, achieving a complete radiological response remains a primary clinical objective to improve long-term outcomes and facilitate potential downstaging [5, 6]. Current guidelines emphasize the importance of personalized dosimetry to optimize therapeutic efficacy, yet the precise mean absorbed dose required to ensure a predictable tumor response has remained a subject of debate [7, 8]. A recent retrospective study now offers specific, evidence-based radiation thresholds for resin microspheres, providing clinicians with concrete targets to optimize tumor response without compromising patient safety.